CannabisPhase 1THC-MemoryNCT02407808
Cannabinoids, Learning, and Memory
A Phase 1 study testing THC in people with Cannabis and Psychotic Disorders, run by Yale University at 1 site in United States.
Trial summary
The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Cannabis, Psychotic Disorders
- What is being tested?
- THC
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 80 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2015to Dec 2027
- Phase
- Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Men and women aged 18 and 55 years (extremes included) on day of first dosing
- Exposed to cannabis at least once in their lifetime
Who cannot join
- Cannabis naive
- Positive pregnancy screen during screening
- Hearing deficits
Trial locations and contacts
1 site in 1 country.
United States1 site
VA Connecticut Healthcare System
West Haven, Connecticut, 06516
About this study
The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.
Read the detailed description
This study will be achieved by studying the acute effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis and a cannabinoid-1 receptor (CB1R) agonist, on a wide range of memory tasks in healthy human subjects.
- Conditions
- Cannabis, Psychotic Disorders
- Being tested
- THC, Placebo
- Medical subject headings
- Marijuana Abuse, Psychotic Disorders
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
THCDrug
Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
PlaceboDrug
Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
| Study group | Role | What they receive |
|---|---|---|
| THC | Active comparator | Active THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes. Receives: Drug: THC; Drug: Placebo |
| Placebo | Placebo comparator | Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes. Receives: Drug: THC; Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Rey Auditory Verbal Learning Test (RAVLT)
a measure of verbal episodic memory
Measured: +35 minutes after infusion
N-Back Task
a measure of working memory
Measured: +65 minutes after infusion
Secondary outcomes (2)
Clinician Administered Dissociative Symptoms Scale (Total Score)
Measured: Baseline, +10, +85, and +240 minutes after the first infusion
Visual Analog Scale (Total Score)
a measure of THC intoxication
Measured: Baseline, +10, +85, +240 minutes after the first infusion
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Apr 2015 (estimated)
- Study startFeb 2015
- Primary completion10 Aug 2018
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CannabisStudies of the same condition, open and under way.
- More trials run by Yale UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Yale University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohini Ranganathan, Yale University
- Investigators
- Mohini Ranganathan, M.D., Principal investigator, Assistant Professor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02407808
- Sponsor's protocol ID
- 1501015211
- Other IDs
- No NIH funding
- Acronym
- THC-Memory
- Status last verified
- Jun 2025
- First submitted
- 31 Mar 2015
- Last updated
- 29 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Cannabinoids, Learning, and Memory
- ClinicalTrials.gov ID
- NCT02407808
- Acronym / sponsor ID
- THC-Memory / 1501015211
- Conditions
- Cannabis, Psychotic Disorders
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 80 participants (estimated)
- Lead sponsor
- Yale UniversityUniversity, hospital or other
- Study start
- Feb 2015
- Primary completion
- 10 Aug 2018 (actual)
- Study completion
- Dec 2027 (estimated)
- First posted
- 3 Apr 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overarching goal of this study is to characterize the effects of cannabinoids on working and episodic memory.
Detailed description
This study will be achieved by studying the acute effects of delta-9-tetrahydrocannabinol (THC), the main psychoactive component of cannabis and a cannabinoid-1 receptor (CB1R) agonist, on a wide range of memory tasks in healthy human subjects.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| THC | Active comparator | Drug: THC, Drug: PlaceboActive THC (0.0015mg/kg-0.03mg/kg) administered over 20 minutes. |
| Placebo | Placebo comparator | Drug: THC, Drug: PlaceboControl: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes. |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Men and women aged 18 and 55 years (extremes included) on day of first dosing
- Exposed to cannabis at least once in their lifetime
Key exclusion criteria (3 listed)
- Cannabis naive
- Positive pregnancy screen during screening
- Hearing deficits
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| THCActive THC (0.0015-0.03 mg/kg) administered over 20 minutes. | Drug | Placebo, THC |
| PlaceboControl: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes. | Drug | Placebo, THC |
Primary outcome
Rey Auditory Verbal Learning Test (RAVLT)
Time frame: +35 minutes after infusion
a measure of verbal episodic memory
N-Back Task
Time frame: +65 minutes after infusion
a measure of working memory
2 secondary outcomes
Clinician Administered Dissociative Symptoms Scale (Total Score)
Time frame: Baseline, +10, +85, and +240 minutes after the first infusion
Visual Analog Scale (Total Score)
Time frame: Baseline, +10, +85, +240 minutes after the first infusion
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Apr 2026.
Related trials for Cannabis
Not yet recruiting
A Hybrid Type 1 Randomized Controlled Trial of an Online and Text-Messaging Intervention to Prevent Alcohol and Cannabis Initiation, Escalation, and Consequences Among First-Year College Students
Alcohol, Cannabis
Not yet recruiting
QAIAx - SGI/SI Smart Health Cities: Microcity Enclave Program (Quantum SI/AGI Agency a/k/a AI City Hall Project - UPSTO App Nos. 64/074,526, 64/063,557, 64/105,164, 63/903,181, 63/729,428, 64/125,360; USPTO EO 9424 Assignment ID: 2101042 / ARN: REEL/FRAME: 76481/0026 - OUSD-R&E, Department of War)
Asperger's Disorder, Asperger Disorder
RecruitingPhase 1
Acute Effects of Cannabis on Cognition and Affect
Cannabis Use
RecruitingPhase 3
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use Disorder
Cannabis Withdrawal
Active, not recruitingObservational study
Cannabis Use and Outcomes in Black and White Patients With Cancer
Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mohini Ranganathan, M.D. principal investigator
Assistant Professor
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing THC in people with Cannabis and Psychotic Disorders, run by Yale University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 29 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Rey Auditory Verbal Learning Test (RAVLT) (time frame: +35 minutes after infusion). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Apr 2026.